Navigation Links
Ranbaxy Launches Asthma Inhalation Capsule in India

Pharma major Ranbaxy Laboratories Ltd Tuesday launched its branded inhalation capsules in India for the treatment of asthma//.

A unique combination of long acting Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, the inhalation capsule Avessa is available as Rheocaps Avessa 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending on the severity of Asthma.

The product is to be used only with the Rheohaler - the world's first capsule-based multi-dose dry powder inhaler, Ranbaxy stated Tuesday.

"We are delighted to launch the world's first unique combination product Avessa in India, which reinforces our strong commitment to develop and introduce convenient solutions for asthmatic patients," said Sanjeev I. Dani, regional director of Ranbaxy for India and the Middle East.

Earlier this year, Ranbaxy had launched Osonide (Ciclesonide) Inhaler, a novel once-a-day product for asthma patients.

In May Ranbaxy entered into an in-licensing agreement for the Indian market with the Netherlands-based pharma company, Eurodrug Laboratories, for the asthma product Doxophylline - a novel Xanthine bronchodilator, sold under the brand name 'Synasma'.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 57518 1Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 57518 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 1Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 3Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 4Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 1Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 2Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 3